Related Experiment Video

Updated: Aug 15, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal

Byung Ha Chung1, Sun Woo Lim, Kyung Ohk Ahn

  • 1Xenotransplantation Center and Cell Death Research Center, Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.

Nephrology (Carlton, Vic.)
|September 22, 2005
PubMed

Insights

Peroxisome proliferator activated receptor gamma (PPARgamma) agonists offer kidney protection beyond diabetes. These agents show renoprotective effects in various kidney diseases through multiple mechanisms.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Peroxisome proliferator activated receptor gamma (PPARgamma) agonists are known for their antidiabetic properties.
  • Emerging evidence suggests PPARgamma agonists possess renoprotective effects in various kidney conditions.

Purpose of the Study:

  • To review the renoprotective effects of PPARgamma agonists in both diabetic and non-diabetic kidney diseases.
  • To elucidate the multifactorial mechanisms underlying PPARgamma agonist-mediated kidney protection.

Main Methods:

  • Literature review of studies investigating PPARgamma agonists in renal injury models.
  • Analysis of proposed mechanisms of action, including anti-fibrotic, anti-inflammatory, and vascular protective effects.

Main Results:

  • PPARgamma agonists demonstrate protective effects in diabetic nephropathy and non-diabetic renal diseases.
  • Observed benefits in models of renal failure, glomerulonephritis, ischemia-reperfusion injury, hypertensive nephropathy, and cyclosporin-induced injury.
  • Proposed mechanisms include anti-fibrotic and anti-inflammatory actions, renin-angiotensin system suppression, vascular protection, and anti-apoptotic effects.

Conclusions:

  • PPARgamma agonists represent a promising therapeutic strategy for kidney protection.
  • Further research into the specific mechanisms can optimize their clinical application in renal diseases.

More Related Videos

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...